Exjade-Early-Trial: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Exjade-Early-Trial (NCT01058369), a non-randomized phase 2 study. The primary outcome is Fraction of Patients With Hematologic Improvement According to Modified IWG Criteria (Reduction of Transfusions and/or Increase in Hb, Improvement of Neutropenia and Thrombocytopenia).

2. Clinical Question

3. Trial Design

The registry identifies Exjade-Early-Trial as a phase 2, prospective, multicentre, single-arm, single-stage study. Its official title describes early treatment with deferasirox in low-risk MDS. The registered allocation is non-randomized, the masking is none, and the model is single group. These features mean the study was set up to observe outcomes in a treated group, not to make a randomized comparison between treatment groups.

The registry record lists deferasirox as the intervention and MDS as the condition. The study outline describes patients with low or INT-1 risk MDS and mild iron overload. The primary outcome was the fraction of patients meeting modified IWG criteria for hematologic improvement within two years. The criteria listed in the outcome description include reduction of transfusions and/or increase in hemoglobin, and improvement of neutropenia and thrombocytopenia.

The recorded start was 2010-04 and the primary completion date was 2013-01. The trial status is terminated. Enrollment is listed as 2, and the primary outcome description states that the study ended prematurely because of insufficient recruitment, before the endpoint was reached by any subject. The record does not report why the recruitment target was insufficient, whether the planned design or conduct changed, or what recruitment target had been intended.

Without a comparator, changes during treatment cannot be separated from changes that might have occurred over time or under other care. Without masking, outcome assessment could also be susceptible to knowledge of treatment, although the record does not describe outcome-assessment procedures. These are design considerations, not evidence that bias occurred in this study.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Trial prematurely ended due to insufficient recruitment before Primary endpoint was reached by any subject

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Fraction of Patients With Hematologic Improvement According to Modified IWG Criteria (Reduction of Transfusions and/or Increase in Hb, Improvement of Neutropenia and Thrombocytopenia), measured over within two years.

The primary endpoint was the fraction of patients with hematologic improvement according to modified IWG criteria within two years. The registry describes improvement as reduction of transfusions and/or increase in hemoglobin, or improvement in neutropenia and thrombocytopenia. This combines several kinds of hematologic change in one endpoint; the record does not specify how the criteria were applied to individual patients or how the components were combined beyond the wording in the outcome description.

In general, a fraction endpoint expresses how often a defined outcome occurs among the people assessed. It can be useful when a study aims to determine whether participants meet a clinically defined response criterion, rather than to estimate only an average change in a laboratory measure. Its interpretation depends on a clear response definition, consistent assessment, and a reported denominator and outcome count.

Those endpoint results are not reported in the registry record. The record states that the trial was prematurely ended for insufficient recruitment before the primary endpoint was reached by any subject. This means the registry does not provide an observed fraction or a precision estimate for hematologic improvement. It should not be read as a finding that participants were assessed and failed to improve; the record instead says the endpoint was not reached before the study ended.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a non-randomized, single-group phase 2 trial. The planned primary outcome was a fraction: the proportion of patients who met modified IWG criteria for hematologic improvement within two years. The registry record does not list a statistical analysis for that outcome. The concepts below are general explanations of how such methods are usually interpreted; they are not claims about analyses performed in this trial.

What does a fraction endpoint represent?

In general, a fraction endpoint counts participants who meet a prespecified definition and relates that count to the number assessed. The definition matters: different response components can yield different classifications unless the rules for combining them are explicit. Here, the listed components are reduction of transfusions and/or increase in hemoglobin, and improvement in neutropenia and thrombocytopenia. The registry does not report an endpoint count, denominator, or detailed adjudication procedure. It says the endpoint was not reached by any subject before premature termination.

What would a confidence interval add?

In general, a confidence interval describes the uncertainty around an estimated effect or fraction under a statistical model. It is not a guarantee that the true value lies within the interval, and it does not resolve limitations in study design or outcome collection. For a fraction, the interval depends on the observed outcome count and the number assessed. Since the registry record does not report a primary endpoint estimate or its denominator, it does not provide a confidence interval from which to judge precision.

Why does the single-group design matter?

In general, a comparison group helps distinguish outcomes associated with an intervention from outcomes that may reflect time, other care, participant characteristics, or chance. Random allocation can help balance measured and unmeasured factors between groups, on average. This trial was not randomized and had one group, so it does not provide a concurrent control comparison. A before-and-after description, if one were available, would still not substitute for a randomized comparison. The registry does not report such a primary-endpoint description in any case.

What does the phase 2 designation say?

The record registers the study as phase 2. In general, a phase designation describes the stage in a clinical development framework; it does not itself establish that a treatment is effective, safe, or supported by a precise estimate. The trial's designation should be read alongside its actual design and status. Here, the record identifies a single-group study that terminated because of insufficient recruitment before the primary endpoint was reached by any subject.

How should the planning assumptions be read?

In general, sample-size calculations are conditional on choices such as the target effect, significance level, allocation, and statistical approximation. The stated planning assumptions use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is described as a stated fraction of the observed effect. These are planning assumptions, not evidence that the registered trial used a two-arm design. The registered design is single group. Sample-size illustrations based on such assumptions are hypothetical planning quantities, not observed power. Observed power is not a substitute for an effect estimate and its uncertainty.

The registry does not report the study's own sample-size justification. The information available also does not establish which target effect, if any, was prespecified for the trial, or whether any planning calculation was used to set recruitment goals. Because the primary endpoint result is not reported, a planning calculation cannot recover the missing outcome information.

What can be concluded from the reported analyses?

The registry lists no analyses. This does not establish which analyses investigators may have conducted outside the registry, but there is no registered analysis result to evaluate. In general, an analysis plan would clarify the primary comparison or estimand, the population included, the handling of missing observations, and the statistical method used to quantify uncertainty. Those details are not reported in the registry record. It would therefore be inappropriate to infer a particular model, adjustment, hypothesis test, or method for handling incomplete follow-up.

The endpoint timeframe was within two years, but the record does not report individual follow-up durations or the status of outcome collection at termination. General time-to-event methods are not automatically relevant to a fraction endpoint: they would require an event-time outcome and appropriate follow-up information. The record lists overall survival and AML-free survival among secondary outcomes, but does not report their analyses or estimates. No survival method can be attributed to this study from the available record.

These distinctions keep the statistical interpretation aligned with what is recorded: a defined intended endpoint, a single-group design, early termination, and no reported primary analysis. General statistical concepts can explain what evidence would usually be needed, but they cannot replace the unreported endpoint data.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists several secondary outcomes, including safety and tolerability, iron depletion, relationships between hematologic improvement and iron depletion or pretreatment parameters, bone marrow morphology, overall survival, and AML-free survival. It also lists the primary endpoint of hematologic improvement. When a study examines multiple endpoints or multiple relationships, the chance of finding an apparently notable result by chance can increase. In general, prespecifying priorities and using an appropriate multiplicity strategy can help make interpretation more disciplined. The registry record does not report a multiplicity adjustment or a plan for prioritizing analyses beyond identifying the primary outcome.

The registry lists no analyses, and it does not report results for the primary or secondary outcomes. It also does not describe the analysis population, whether all enrolled participants were intended to be analyzed, or how missing observations would be handled. Those details are important because an outcome fraction depends on who was assessed and how incomplete observations are treated. No missing-data method or sensitivity analysis is reported in the registry record.

The primary outcome description says the trial ended prematurely because of insufficient recruitment before any subject reached the endpoint. This is not the same as a reported endpoint analysis in which every assessed participant failed to meet the response definition. The registry does not explain whether outcome follow-up stopped for all participants, whether any endpoint components were observed, or how discontinuation and incomplete follow-up were documented.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (50.0%), acute myeloid leukaemia (50.0%).

The registry lists adverse-event figures for the Deferasirox group. For serious adverse events, 2 were at risk and 1 was affected. For other adverse events, 2 were at risk and 2 were affected. These are separate listings; they should not be added together or treated as interchangeable categories. The record also lists Pneumonia and acute myeloid leukaemia among the top serious terms, each at 50.0%.

These figures are descriptive of the registry record. They do not, by themselves, show that deferasirox caused an event, and a single-group study cannot compare the listed figures with a concurrent untreated or alternative-treatment group. With enrollment listed as 2, the information is too limited to characterize safety precisely or to generalize event frequencies to a broader population. The registry record does not report event timing, severity grades, relationship assessments, or further clinical detail for these terms.

Deaths are not reported in the record. That absence should not be interpreted as evidence that no deaths occurred; the registry does not provide a death count.

12. What the Result Does, and Does Not, Mean

The record establishes that investigators registered a prospective, multicentre, single-group phase 2 study of deferasirox for low-risk MDS with mild iron overload. Its primary question concerned hematologic improvement within two years under modified IWG criteria. The study was terminated because recruitment was insufficient, before the primary endpoint was reached by any subject. This is the central result available for interpreting the trial.

It does not provide an estimate of the fraction achieving hematologic improvement, a confidence interval, or a statistical test for the primary endpoint. Therefore, it does not establish how often the specified improvement occurred in the study population or how precisely that frequency could be estimated. Nor should early termination be read as proof that treatment failed: the registry describes a recruitment-related termination before the endpoint was reached, not a reported analysis showing lack of improvement.

The design also does not provide a treatment comparison. Because the study had one non-randomized group and no comparator, it cannot show whether outcomes differed from those under another treatment or no treatment. Any observed event or change in a single group would not by itself establish that the intervention caused it. In this record, the primary endpoint result itself is not reported.

The adverse-event listings offer limited descriptive information but do not establish a causal relationship or comparative safety profile. The record's enrollment and incomplete outcome reporting constrain interpretation of both efficacy-related and safety-related observations. The registry does not report the analysis population, missing-data methods, or analyses of its secondary outcomes.

The appropriate conclusion is narrow: the registry records the intended study question and design, and reports premature termination for insufficient recruitment before the primary endpoint was reached by any subject. It does not supply evidence sufficient to estimate hematologic improvement or to draw a comparative treatment conclusion.

13. Why This Trial Matters Statistically

This trial is statistically informative in part because it illustrates the distinction between a prespecified question and an answer supported by data. A clearly described primary endpoint does not ensure that an estimate can be produced. The registry identifies a fraction of patients with hematologic improvement as the primary outcome, but also states that the study ended before any subject reached that endpoint. The intended measure and the available result are therefore different things.

Early termination for recruitment insufficiency affects what can be learned even when the clinical question is important. Enrollment is listed as 2, and the registry does not provide a primary endpoint estimate or analysis. General statistical principles indicate that small amounts of information limit precision; without outcome counts and a denominator, however, precision cannot be quantified for this endpoint. Reporting the reason for termination helps readers avoid treating the absence of a result as a negative result.

The single-group, non-randomized design is also important. It can describe observations in the treated group if outcomes are collected and reported, but it cannot provide a randomized estimate of comparative effect. This is a design limitation, not a claim that a particular bias occurred. Clear separation of description from causal comparison is essential when interpreting one-group studies.

Finally, the record makes visible what is not documented: primary analyses, analysis populations, and missing-data procedures are not reported. That distinction matters for researchers and clinicians reading registries, because an absent result may reflect an incomplete study record rather than a measured outcome. The trial's statistical contribution is chiefly a reminder that outcome definitions, recruitment, follow-up, and transparent reporting all shape whether a planned question can be answered.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations are specific to this record. First, the trial is marked terminated and the primary outcome description attributes this to insufficient recruitment. Enrollment is listed as 2, and no endpoint was reached by any subject before the study ended. The record does not report a primary outcome estimate, its denominator, or a precision measure. It is consequently not possible to evaluate the intended hematologic-improvement endpoint from these registry results.

Second, the study had a single group, with non-randomized allocation and no masking. There is no like-for-like control group in the registered design. The record therefore cannot separate outcomes observed during treatment from what might have occurred under another treatment or without the intervention. The registry does not describe outcome-assessment procedures, so the effect of the absence of masking on assessment cannot be evaluated.

Third, the record does not give detailed eligibility criteria, participant characteristics, follow-up completeness, the analysis population, or missing-data methods. It does not report why recruitment was insufficient or whether the study's intended recruitment plan changed. The registry lists no analyses and provides no reported results for the primary endpoint. These omissions limit assessment of both the conduct and the statistical analysis.

Finally, the adverse-event listings are descriptive and come from a small single-group study. The record does not report event timing, relationship to treatment, or death count. Its secondary outcomes are listed but no analyses or estimates are reported. These gaps mean the record cannot support precise conclusions about efficacy, comparative safety, or the broader population described in the study outline.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Exjade-Early-Trial — NCT01058369.
• Registry record last updated 2020-10-06; status last verified 2020-09.
• Results first posted 2020-10-06.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

Exjade-Early-Trial (NCT01058369) is registered as a phase 2, prospective, multicentre, non-randomized, single-group study of deferasirox in low-risk MDS with mild iron overload. The primary endpoint was the fraction of patients with hematologic improvement according to modified IWG criteria within two years.

The recorded start was 2010-04 and primary completion was 2013-01. The trial status is terminated, with enrollment listed as 2. The registry states that insufficient recruitment led to premature termination before the primary endpoint was reached by any subject. No analyses are listed, and no primary endpoint estimate is reported. The adverse-event listings are descriptive and do not establish causation or comparative safety.